Trial Profile
ASSESSMENT OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH METASTATIC BREAST CANCER SWITCHED FROM INTRAVENOUS ZOLEDRONIC ACID THERAPY TO ORAL IBANDRONATE
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary) ; Zoledronic acid
- Indications Breast cancer
- Focus Therapeutic Use
- 09 Nov 2016 New trial record